Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free. Our insightful and holistic reports have helped corporates, academia and researchers take their research forward. You also agree to receive email updates from us on our new reports and solutions.

Moderna SWOT & PESTLE Analysis

ID : 52789753| Oct 2020| 15 pages

COMPANY PROFILE -Moderna

Business Sector :Biotechnology

Operating Geography :USA, North America

About Moderna :

Moderna Inc. functions as a messenger RNA therapeutics biotechnology company. The firm is developing and researching drugs to generate proteins or antibodies inside human cells. Instead of being produced externally and inserted as in traditional drugs, the Moderna Technology Platform is to implant synthetic mRNA into living cells that will reprogram the cells to establish immune responses. It is an innovative approach abandoned by many major pharmaceutical and biotechnology firms who have been unable to resolve the side effects of RNA injection into cells. Different medication modes such as prophylactic vaccinations, preventive vaccines, intra - tumoral immuno-oncology, targeted therapeutics and intracellular liver are included in the pipeline. Moderna also offers therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology and cardiovascular disease. It is headquartered in Cambridge, Massachusetts, the US. In December 2018, Moderna became the highest initial public biotech offering (IPO) in history, raising US$ 600 million for 8% of its shares, indicating overall valuation of $7.5 billion.
Moderna’s mission is to “Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.”

Moderna Revenue :


US$ 60.2 million – FY ended Dec 31st 2019 (YoY growth negative 55.4%)
US$ 135.1 million - FY ended Dec 31st 2018

Competitive Analysis of Moderna

SWOT
PESTLE
The SWOT analysis for Moderna is presented below:
Strengths
Weaknesses
1. Strong proprietary infrastructure
2. Strategic alliances to accelerate advancement of potential mRNA drugs
3. Patent and IP estate as strategic assets
4. Leading candidate for COVID-19 vaccine
1. Poor track record with no marketable product and no revenue
2. Continuous losses since inception
3. Lack of experience in sales and distribution
Opportunities
Threats
1. Massachusetts as a booming biotech hub
2. mRNA potential for new class of medicines
3. Untapped local production
1. Massachusetts as a booming biotech hub
2. mRNA potential for new class of medicines
3. Untapped local production
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Detailed SWOT Analysis of Moderna

 

Strength

This section is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

1. Threat to and from scaling of COVID-19 vaccine: Moderna's commitment of substantial resources to a public health problem i.e. COVID-19 that is uncertain and may rapidly disperse, or against which their vaccine would not be partially or entirely effective if created, could have a negative impact on business. Furthermore, another group may succeed in creating a more efficient vaccine or other medication that may also contribute to the transfer of governmental and quasi-governmental funds away from Moderna and to other businesses. Even if they succeed in developing a vaccine, they will need to commit considerable resources, including for use by the US government, to its scale-up and growth. In this scenario, substantial resources will need to be allocated to this initiative, which may require the transfer of money from their other initiatives. In these conditions, unforeseen safety concerns could lead to substantial reputational harm to Moderna and their technology platform and other problems, including delays in other projects, the need for clinical trials to be re-designed and the need for considerable additional financial capital.

2. Dependence on progression of modalities: Moderna's business is heavily dependent on the clinical progress of their initiatives and modalities. Their sector may be negatively impacted by delay or inability to progress programs or modalities. This could be the consequence of technological problems that are unique to the program or because of the biological danger that is unique to each program. As Moderna advance programs through clinical growth, new technological problems can emerge that trigger failure of an entire modality. Although the company strives to segregate risk through modalities, there can be, in whole or in part, foreseen and unforeseen risks throughout modalities. This involves mRNA, chemical modifications, and LNPs and their elements, although they are not limited to them. Furthermore, if one or more of clinical projects face difficulties with safety, tolerability, or feasibility, developmental delays, regulatory problems, or other concerns, their approach to the product and market may be substantially harmed. Besides that, in much of their pipeline, the biological risk reflects targets and pathways not scientifically confirmed by one or more licensed drugs.

The remaining section of “Threat” is available only in the 'Complete Report' on purchase.

SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Check Out Analysis of Other Relevant Companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Moderna Analysis Report

1. Moderna Investors Report 2019 - https://investors.modernatx.com/static-files/16245ad7-c5e0-4671-82c3-a783b0c0099a

2. Moderna Annual Report 2019 - https://sec.report/Document/0001682852-20-000006/

3. 10 Covid-19 vaccines that are ahead of the pack - https://www.moneycontrol.com/news/coronavirus/heres-status-update-on-10-covid-19-vaccines-that-are-ahead-of-the-pack-5882971.html

4. Moderna: Promising COVID-19 Vaccine Does Not Justify Its Current Market Cap - https://seekingalpha.com/article/4338529-moderna-promising-covidminus-19-vaccine-not-justify-current-market-cap

The detailed complete set of references are available on request in the 'Complete report' on purchase.

How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

Moderna SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2020). Moderna SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/moderna/ [Accessed 28 Oct, 2020].

In-text: (SWOT & PESTLE.com, 2020)

Copyrights and Disclaimer

Moderna SWOT and PESTLE analysis has been conducted by Anirudh Gupta and reviewed by senior analysts from Barakaat Consulting.

Copyright of Moderna SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

You might also like to check out :
Moderna SWOT & PESTLE Analysis
Price : USD 12.53